Where is Savient Pharmaceuticals, Inc.'s stock traded?
Savient Pharmaceuticals, Inc. common stock is traded on the NASDAQ National Market under the ticker symbol "SVNT."
Where are Savient Pharmaceuticals, Inc.'s headquarters located?
One Tower Center
Fourteenth Floor
East Brunswick, NJ 08816
Can I buy Savient Pharmaceuticals, Inc.'s stock directly from the Company?
Savient Pharmaceuticals, Inc. does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.
Does Savient Pharmaceuticals, Inc. have any other locations?
Savient Pharmaceuticals, Inc.
16870 West Bernardo Drive
Suite 400, Room 405
San Diego, CA 92127
Tel: (858) 674-6650
Does Savient Pharmaceuticals, Inc. pay a dividend?
Savient Pharmaceuticals, Inc. does not currently pay dividends.
Who is Savient Pharmaceuticals, Inc.'s transfer agent?
American Stock Transfer & Trust Company
59 Maiden Lane
Plaza Level
New York, NY 10038
800-937-5449 www.amstock.com
Who do I contact about replacement of stock certificates?
To replace lost certificates, contact the transfer agent,
American Stock Transfer & Trust at 800-937-5449
What is Savient Pharmaceuticals, Inc.'s fiscal year?
Savient Pharmaceuticals, Inc.'s fiscal year is based on the calendar year.
First Quarter ends 3/31, Second Quarter ends 6/30,
Third Quarter ends 9/30 and Fourth Quarter ends 12/31.
Do you have another question that hasn't been answered?
Please submit your question using the form below. Fields marked with an * are required.
Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investor Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.
The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in the website are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding whether our KRYSTEXXA BLA resubmission, combined with the submissions made and planned by our third party contract manufacturer, fully addresses the deficiencies and observations raised and provides the additional materials requested in the Complete Response Letter that we received from the FDA on July 31, 2009, which were further clarified in our meeting with the FDA on September 14, 2009, the timing of FDA action with respect to the BLA resubmission, potential FDA marketing approval for KRYSTEXXA™, the efficacy and safety of KRYSTEXXA and the potential regulatory filings outside the United States and the potential for marketing approval in those jurisdictions are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 and Open Label Extension Study clinical data, our current understanding of the Complete Response Letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA, our third party contract manufacturer or require that we conduct additional clinical trials; our reliance on third parties to manufacture, market and distribute many of our products; our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this website to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.
expand all
collapse all